Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity von White, Deborah L., Saunders, Verity A., Dang, Phuong, Engler, Jane, Venables, Amity, Zrim, Stephanie, Zannettino, Andrew, Lynch, Kevin, Manley, Paul W., Hughes, Timothy

Volltext

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis von Hiwase, Devendra K., White, Deborah L., Saunders, Verity A., Dang, Phuong, Venables, Amity, Eadie, Laura, Zrim, Steph, To, L. Bik, Melo, Junia V., Hughes, Timothy P.

Volltext

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Do... von White, Deborah, Saunders, Verity, Dang, Phuong, Venables, Amity, Zrim, Steph, Reynolds, John, Quinn, Steven, Zannettino, Andrew, Hughes, Timothy

Volltext

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance von White, Deborah, Dang, Phuong, Venables, Amity, Saunders, Verity, Zrim, Stephanie, Zannettino, Andrew, Diamond, Peter, Quinn, Steven, To, Luen Bik, Hughes, Timothy

Volltext